Lab for Home 1

Boehringer Ingelheim acquires Pharmaxis' phase 1a drug

Boehringer

Boehringer Ingelheim and Pharmaxis announce that Boehringer Ingelheim has exercised its option and acquired the investigational drug PXS4728A, to develop it for the treatment of the liver-related condition NASH and to prevent its consequences.

Find out more

istock 000019115467 smaller1

Bronchitol Paediatric Cystic Fibrosis Clinical Trial Reports Positive Results

Pharmaceutical research company Pharmaxis (ASX: PXS) is pleased to announce positive results of its recently completed Phase II trial of Bronchitol® (mannitol) in children and adolescents with cystic fibrosis (CF). The trial, conducted across 39 global centres, met its primary endpoint and confirms that Bronchitol is efficacious in young patients, regardless of concomitant dornase alfa use.

Find out more

2016 03 29 AQ05701

Synairgen Collaboration Progress

Pharmaxis has reported progress in its ongoing collaboration with UK biotechnology company Synairgen plc (LSE: SNG) to develop a selective inhibitor to the lysyl oxidase type 2 enzyme (LOXL2) to treat the fatal lung disease idiopathic pulmonary fibrosis (IPF).

Synairgen released data generated in an in vitro model of IPF using lung cells from IPF patients, developed in collaboration with scientists at the University of Southampton. The data shows that the Pharmaxis enzyme inhibitors, by inhibiting LOXL2, are able to reduce cross-linking of collagen fibres essential for the stabilization of fibrotic tissue.

Read more